Forecast
| Buy |
Â
0 |
| Hold |
Â
0 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Avacta Therapeutics publishes 2025 annual report and calls annual general meeting for 22 June
Avacta Therapeutics has published the annual report for the year ended 31 December 2025 and convened the annual general meeting for Monday, 22 June 2026 at 09:00 BST at Glaziers Hall, London. Shareholders who chose postal distribution will receive the papers today; registered shareholders may attend in person or be represented by a proxy. Attendance requires pre-registration and proof of share ownership by email by 20 June 2026, 20:00 BST, although failure to register does not prevent attendance or appointment of a proxy. After the meeting Avacta plans to give an update on business developments; presentation materials and a recording will be made available on the website. » More on de.investing.com
Avacta CEO Christina Coughlin named "Rising Leader 2026" by In Vivo
Avacta announced that CEO Christina Coughlin was included on the "Rising Leaders 2026" list by the trade publication In Vivo. Coughlin, MD PhD, has led the company for two years and previously worked as an oncologist. Chairman Shaun Chilton emphasized that under Coughlin's leadership the drug candidate AVA6103 was advanced from research to treatment of the first patients in a phase‑1a study within 24 months. » More on de.investing.com
Avacta plans capital increase of ÂŁ10m to finance clinical programmes
Avacta will raise about £10m by placing 15m new shares plus 873,016 shares in a subscription at 63 pence each (9.35% discount). The proceeds are intended to serve as working capital to fund research and development programmes into early Q1 2027 and to extend the runway through the first readout of the Phase‑1a study of AVA6103 (first readout end‑2026). Dosing of AVA6103 is imminent, Phase‑1b expansion cohorts for Faridoxorubicin are nearly recruited; two non‑executive directors intend to participate in the subscription and Zeus Capital is acting as broker, with an accelerated bookbuild having been launched. » More on de.investing.com
Avacta reports promising study data and secures funding through Q3 2026
Avacta reports positive results for its cancer therapies: AVA6000 showed a disease control rate of 90% in salivary gland cancer, and FAP-Exd (AVA6103) is expected to enter clinical testing in Q1 2026. The company closed 2025 with £16.9m in cash, raised £22.5m of equity and generated over £15m from the sale of non-core diagnostics businesses. Available liquidity covers the planned clinical programmes and the preclinical pipeline through the third quarter of 2026. Avacta is expanding its intellectual property and is in talks with potential pharmaceutical partners, with particular interest in the FAP-Exd programme. » More on de.investing.com
Avacta reports promising preclinical data for cancer drug FAP-Exd
Avacta reports that the peptide‑drug conjugate FAP-Exd (AVA6103) showed tumor‑specific release of the payload over five days in preclinical studies, along with robust antitumor activity and broader cytotoxicity compared with Exatecan. The drug remains in the tumor for five days but is cleared from blood plasma within two hours. Phase 1 studies are planned to start in Q1 2026; the clinical program was designed using artificial intelligence to identify promising cancer indication combinations. » More on de.investing.com
Financials
In the last quarter, AVACTA GROUP PLC LS-,10 had revenue of €65.35k and net profit of -€22.2m
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 65.35k | - |
| Gross profit | -590.51k | - |
| Net profit | -22.2m | - |
| EBITDA | -16.38m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €341.6m |
Number of shares | 486.79m |
52-week high/low | €1.12 - €0.67 |
| Dividends | No |
Beta | -0.10 |
P/E ratio | -6.47 |
PEG ratio | -0.37 |
P/B ratio | 70.36 |
P/S ratio | 2,541.63 |
Company profile
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
| Name | AVACTA GROUP PLC LS-,10 |
| CEO | Christina Marie Coughlin |
| Headquarters | London,
gl United Kingdom |
| Website | |
| IPO | 02/01/2008 |
| Employees | 154 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | AVCT.L |
Pnk | AVCTF |
Frankfurt | RTQ1.F |
London | AVCT.L |
DĂĽsseldorf | RTQ1.DU |